INTRODUCTION
Patients with cancer have a four-to eight-fold higher risk of venous thromboembolic events (VTEs) than age-matched controls. [1] [2] [3] Several clinical characteristics have been associated with increased risk of VTEs in patients with cancer, including more advanced disease, poor performance status, and multiple comorbidities.
3, 4 Although the presence of malignancy itself and its associated physiologic changes are likely major contributors to an increased risk of VTEs, several cancer treatments, including hormonal therapies, cytotoxic agents, and supportive care medications, have also been associated with increased rates of VTEs. [5] [6] [7] [8] [9] Importantly, patients with cancer who experience VTEs have worse prognosis and an increased risk of death. 10, 11 Cisplatin, a DNA cross-linking agent integral to the treatment of a diverse array of malignancies used since the 1970s, has been commonly associated with an increased risk of VTEs. [12] [13] [14] [15] However, this association is mostly based on case reports, single-arm prospective studies, and retrospective analyses. For example, Moore et al 16 recently reported a retrospective analysis of 932 patients with solid malignancies receiving cisplatin-based chemotherapy at a single institution, in which 18% of patients experienced a thromboembolic event. A single phase III trial prospectively explored rates of VTEs in patients with advanced gastroesophageal cancer randomly assigned to receive cisplatin-versus oxaliplatin-based regimens. There were fewer thromboembolic events in the oxaliplatin groups compared with the cisplatin groups JOURNAL OF CLINICAL ONCOLOGY (7.6% v 15.1%; P Ͻ .001), and cisplatin was identified as a risk factor for thromboembolism in the multivariate analysis. 17 Although compelling, these findings are limited by retrospective design or a single tumor type. In fact, the overall level-1 evidence supporting an excess risk of VTEs with cisplatin-based chemotherapy is scant in the context of the large number of patients receiving cisplatin worldwide each year. Therefore, we performed an up-to-date systemic review and meta-analysis to evaluate the effect of cisplatin on thromboembolism in patients with cancer.
METHODS

Data Source
The selection and systematic review of trials was performed in accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement. 17 An independent review of PubMed citations published from January 1, 1990 , to December 31, 2010, was conducted. Search terms included: cisplatin, cancer, and randomized clinical trial. Only trials published in peer-reviewed publications in full manuscript form in English were eligible. Only the most recent publication was included when duplicates were identified.
Study Selection
Our primary objective was to evaluate the association between treatment with cisplatin-based chemotherapy and VTEs in patients with cancer. Clinical trials meeting the following criteria were included in the meta-analysis: one, prospective randomized phase II and III trials of patients with cancer; two, randomized assignment of participants to treatment with cisplatin-versus non-cisplatin-containing chemotherapy; and three, available data on thromboembolic events. In an effort to minimize imbalances in central venous catheter-associated thrombosis, trials involving prolonged infusional drug regimens in one arm (eg, continuous fluorouracil infusion) were excluded. Methodologic quality was assessed using the Jadad scale, an instrument based on trial design elements such as blinding and randomization, to rank trials from 0 to 5.
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Data Extraction and Clinical End Point
Data extraction was independently performed by two investigators (S.K.C., T.P.-S.) according to PRISMA guidelines. Discrepancies were resolved by consensus among a panel of reviewers (S.S., M.D.G., S.K.C., T.P.-S.). For each study, we extracted the PubMed identification number, year of publication, trial phase, treatment arms, underlying malignancy, number of participants enrolled, number of participants evaluable for toxicity, sex, median age, cisplatin dose (mg/m 2 ), median follow-up duration, and toxicity data of interest including the number of all-grade VTEs. The number of patients evaluable for toxicity was used as the number analyzed, unless this was not indicated, in which case the number of patients enrolled was used. Because cisplatin dose and schedule varied widely, we calculated a standardized equivalent weekly dose by dividing the dose of cisplatin administered by frequency or schedule. The primary end point was the incidence of VTEs. Adverse events were defined by criteria established by the WHO, Cancer and Leukemia Group B, or National Cancer Institute Common Terminology Criteria for Adverse Events, Version 2 or 3. All reported thromboembolic events were recorded and classified as deep venous thrombosis, pulmonary embolism, or thromboembolism unspecified. All thromboembolic events were captured, regardless of attribution assigned in the original publication.
Statistical Analysis
Analyses were performed using R statistical software with the metafor package.
19 Random effects models were used uniformly regardless of the actual interstudy heterogeneities, which were quantified using the I 2 statistic. Individual trials were pooled and weighted using the DerSimonianLaird method. 20 Continuity corrections with 0.5 were adopted for trials with zero events in either the cisplatin or control arm or both arms. The incidence and relative risk (RR) of VTEs were calculated for each study, along with appropriate 95% CIs and P values. Given concerns over whether random effects models are applicable to rare events, RRs were also pooled using the Mantel-Haenszel method. Compared with the random effects model, this analysis (Appendix Table A1 , online only) revealed slightly higher RRs for the overall population and subgroups but did not alter the study conclusions. A two-sided P value Ͻ .05 was considered significant. Metaregression was planned to evaluate the impact of covariates on overall heterogeneity using study-level median age and percentage of male patients. However, this planned analysis was not performed because the estimated total amounts of heterogeneity and I 2 were both zero. Prespecified subgroup analyses were performed according to publication year, tumor type, cancer stage, cisplatin dose, and trials evaluating cisplatin versus another platinum agent or nonplatinum chemotherapy. All subgroup analyses followed the same meta-analysis procedure. Heterogeneity tests for the subgroup analyses were performed by metaregression using dummy variables, as suggested by Deeks et al.
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RESULTS
Search Results
Our search identified 2,359 potentially relevant articles. All abstracts were screened, and 1,810 studies were excluded. The selection process and reasons for exclusion are detailed in Figure 1 . A total of 38 randomized trials were included in the final analysis, including 19 phase II and 19 phase III trials.
Study Quality
All included trials involved randomized treatment allocation. None were placebo controlled or double blind, which would be difficult given the hydration and antiemetic therapy necessary with cisplatin. The median Jadad score was 3 (range, 2 to 3). Because none of the trials were blinded, the highest Jadad score was 3.
Publication Bias
No evidence of publication bias was detected for the primary end point using the Begg test (P ϭ .55).
Study, Patient, and Treatment Characteristics
A total of 8,216 patients from 38 randomized phase II and III trials (cisplatin, n ϭ 4,154; control, n ϭ 4,062) were included. The characteristics of each trial are summarized in Table 1 . Three trials evaluated perioperative chemotherapy, and 35 trials evaluated chemotherapy for patients with advanced/metastatic disease. The control chemotherapy regimens consisted of non-platinum-based therapy in 24 trials and a different platinum agent (carboplatin, 12; oxaliplatin, two) in 14 trials. The most common malignancies were non-smallcell lung cancer (15), gastric/esophageal junction cancer (eight), small-cell lung cancer (three), pancreatic cancer (three), and head and neck cancer (three). Of the 38 trials, 20 involved cisplatin administered every 3 weeks, with doses ranging from 40 to 80 mg/m 2 . Patients with active thromboembolic disease, receiving anticoagulation, or with poor functional status were excluded from enrollment in the vast majority of trials.
Incidence of VTEs
There was significant heterogeneity in the incidence of VTEs among patients receiving cisplatin, ranging from 0% to 17% in the 38 included trials (n ϭ 8,216 patients). The highest incidence (17%; 95% CI, 8.21% to 32.58%) of VTEs was observed in a trial of 80 patients with urothelial cancers treated with methotrexate, vinblastine, doxorubicin, and cisplatin. 31 Thirteen trials in the meta-analysis reported no VTEs in either the treatment or control arms. On the basis of a random effects model, the summary incidence of VTEs was 1.92% (95% CI, 1.07% to 2.76%; I 2 ϭ 87.95%) in patients receiving cisplatinbased therapy and 0.79% (95% CI, 0.45% to 1.13%; I 2 ϭ 34.56%) in patients receiving noncisplatin regimens.
RR of VTEs
A meta-analysis was performed to calculate the overall RR of VTEs associated with cisplatin-versus non-cisplatin-based chemotherapy (Fig 2) . The I 2 statistic was 0.00%, and the RR of VTEs for cisplatin-versus non-cisplatin-based chemotherapy was 1.67 (1.92% v 0.79%; 95% CI, 1.25 to 2.23; P ϭ .01).
Many trials did not specify the grade of thromboembolic events, precluding an analysis of VTE severity. In addition, various terms were used to describe thromboembolic events, precluding an analysis of specific event types. Thromboembolic events in the cisplatin and controls arms were therefore categorized as pulmonary embolism, deep venous thrombosis, or thromboembolism unspecified. The events, categorized using these terms, are summarized in Table 2 . Importantly, although a description of specific type of event was lacking for the thromboembolism unspecified category, severity information was available for most of these events, highlighting their clinical significance. Among the 41 unspecified events in the cisplatin arm, 38 were grade 3 to 4, and three were grade 1 to 2. All 23 unspecified events in the control arm were grade 3 to 4.
Influence of Cisplatin Dose and Control Regimen on RR of VTEs
To better understand the relationship between cisplatin and VTEs, we performed several exploratory analyses, stratifying patients by cisplatin dose, malignancy, control arm chemotherapy, and year of publication ( was unique to cisplatin or common to all platinum agents. Interestingly, the effect size was greater in the analysis comparing cisplatinbased chemotherapy with regimens containing other platinum agents (RR, 1.96; 95% CI, 1.38 to 2.78; P ϭ .01) versus the analysis comparing cisplatin-based chemotherapy with nonplatinum regimens (RR, 1.22; 95% CI, 0.74 to 2.00; P ϭ .43); however, there was no significant difference between these subgroups.
Influence of Underlying Tumor Type on RR of VTEs
Given the potentially differing risks of VTE among patients with different tumor types, an exploratory analysis stratifying patients by tumor type was performed (Table 3 ). The incidence of VTEs was highest among patients with gastric/esophageal cancer (4.84%; 95% CI, 1.61% to 8.06%), followed by pancreatic cancer (2.10%; 95% CI, 0% to 4.51%) and small-cell lung cancer (1.36%; 95% CI, 0.85% to 2.64%). The effect sizes varied, but the differences among tumor types were not statistically significant.
Influence of Publication Year on RR of VTEs
We hypothesized that the incidence of VTEs reported in cancer clinical trials may have increased over the past decade because of the increased use of high-resolution computed tomography with resultant incidental detection of pulmonary emboli. Therefore, we explored the impact of publication year on incidence and RR of VTEs with cisplatin-based therapy. Notably, the incidence of VTEs in the 10 trials published from 1990 to 1999 was 0.69% (95% CI, 0.15% to 1.23%), compared with an incidence of 2.67% (95% CI, 1.40% to 3.95%) in the 28 trials published from 2000 to 2010. In the 28 trials published from 2000 to 2010, cisplatin-based chemotherapy was associated with an RR of VTEs of 1.72 (95% CI, 1.27 to 2.34). In trials published from 1990 to 1999, cisplatin-based chemotherapy was associated with an RR of VTEs of 1.30 (95% CI, 0.53 to 3.20). This difference did not reach statistical significance.
DISCUSSION
Venous thromboembolic disease is a major cause of morbidity and mortality in patients with advanced solid tumors.
11,59,60 We sought to comprehensively examine the relationship between cisplatin-based Gredelli Relative Risk (log scale)
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Fig 2.
Relative risk of venous thromboembolic events (VTEs) associated with cisplatin-versus non-cisplatin-based chemotherapy. RE, random effects. chemotherapy and VTEs in patients with cancer by pooling data from randomized clinical trials conducted in the past two decades. Indeed, our meta-analysis of 8,216 patients from 38 randomized trials revealed that compared with patients not receiving cisplatin-based chemotherapy, those receiving cisplatin-based chemotherapy had a 1.67-fold increased likelihood of experiencing a thromboembolic event.
The pathogenesis of cisplatin-induced thrombogenicity remains unclear, although several studies have suggested potential mechanisms. Cisplatin induces endothelial injury, platelet activation, and upregulation of prothrombotic factors, all of which have been implicated in thrombogenicity. [61] [62] [63] Cisplatin-induced renal dysfunction may also play a contributing role; the risk of VTEs is higher in patients with renal impairment. 4 There are several potential limitations to our analysis. Although the incidence of VTEs varied among the included trials, it was relatively low compared with the incidence reported in several retrospective and prospective studies with VTEs as a primary end point.
14,15, [64] [65] [66] In fact, the only clinical trial with VTEs as a primary end point included in our analysis accounted for a large number of VTE events. 17 Khorana et al 67 previously highlighted limitations in estimating the risk of VTEs in patietns with cancer, including heterogeneity among studies, inclusion criteria, and follow-up duration and differences in screening, diagnosing, and reporting of VTEs. A meta-analysis by Reynolds et al 68 evaluating clinical trial design and VTEs demonstrated that the incidence of VTEs increased up to 55 times when they were actively surveyed versus passively identified. Furthermore, patients enrolled onto randomized phase II and III trials meet rigorous eligibility criteria, which excludes many patients at higher risk for VTEs. These limitations likely resulted in an underestimation of the incidence of cisplatin-associated VTEs. However, the determination of excess risk of VTEs associated with cisplatin-versus non-cisplatin-based chemotherapy, the ultimate goal of our study, was unlikely affected, because this underestimation should have had a similar impact on both arms. Several included trials reported zero VTEs in one or both arms. We acknowledge that in this setting, random effects models and continuity corrections would bias the results toward null. 69 We felt that including trials reporting zero VTEs would provide the most conservative estimate of incidence, and these trials would be excluded if the Mantel-Haenszel method were used. A bias toward null means that some true differences might have been missed. However, even in the context of this limitation, we detected a significant increase in the RR of VTEs, adding further confidence in the results. Given concerns that random effects models may not be ideal for evaluation of rare events, we also performed our analysis using the Mantel-Haenszel method (Appendix Table A1 , online only), which revealed larger pooled RRs but did not alter the study conclusions. In some trials, there were treatment regimen differences aside from cisplatin (eg, methotrexate, vinblastine, doxorubicin plus cisplatin versus paclitaxel plus carboplatin), and we cannot rule out that increased thrombogenicity associated with other regimen components could have influenced the results. We found that the diagnosis, reporting, and definition of thromboembolic events varied widely across trials. We included all trials that specifically reported any thromboembolic data (even if no VTEs occurred in either arm). Of the 549 trials assessed for full eligibility, 456 trials were excluded because no VTE data were reported. When reported, severity grading was often missing, precluding an independent analysis of the risk of high-grade events. Many events (34%) were categorized simply as thromboembolic events. However, severity grading was available for the majority of such events, confirming their high-grade, clinically relevant nature.
Recent studies evaluating the excess risk of VTEs with antiangiogenic therapy have raised the possibility that the excess risk in some meta-analyses may have been mistakenly related to patients receiving treatment longer in antiangiogenic therapy-containing treatment arms compared with those in controls arms, because of a progression-free survival benefit observed with the former.
7,70
However, the vast majority of trials included in our analysis did not demonstrate such an improvement in progression-free survival in the cisplatin-containing arms. Our exploratory subgroup analyses revealed some interesting, hypothesis-generating findings. The RR for VTEs was highest in the subgroup receiving a weekly normalized cisplatin dose Ͼ 30 mg/m 2 .
Although the lack of a linear increase in RR with increasing dose does not support a dose-response relationship, a threshold effect cannot be ruled out. Specific underlying malignancies have been associated with varying risks of VTEs. 71, 72 The effect sizes varied with regard to the RR of VTEs in specific tumor types, although interpretation of these findings are hampered by the low number of patients and events in certain subgroups. We hypothesized that the incidence of VTEs reported in clinical trials over the last decade may have increased because of the use of higher-resolution cross-sectional imaging (and incidental detection of pulmonary emboli) and perhaps an increased awareness that VTEs may be treatment rather than disease related. 71, 73, 74 Indeed, the incidence of VTEs was higher in trials published between 2000 and 2010 compared with trials published between 1990 and 2000. Finally, we observed an increased risk of VTEs with cisplatin even within the subgroup of trials comparing cisplatin-based with other platinumbased regimens, suggesting that the excess risk of VTEs may be unique to cisplatin rather than a common feature of platinum drugs. These latter two subgroup analyses were also likely influenced by the Starling et al 17 trial.
Although postulated based on case reports, retrospective analyses, nonclinical mechanistic studies, and a single prospective randomized trial, to our knowledge, this is the largest study evaluating the excess risk of VTEs with cisplatin-based chemotherapy. We observed a 1.67-fold increase in the risk of VTEs with cisplatin as compared with non-cisplatin-based chemotherapy. These findings should be viewed in the context of a recent meta-analysis suggesting a 1.33-fold increased risk of VTEs with bevacizumab, an anti-vascular endothelial growth factor receptor antibody, which has been used for decades less frequently than cisplatin to treat a fraction of the malignancies. Given the morbidity and mortality associated with VTEs in patients with cancer, our study adds further support to calls for prospective trials of cisplatin-based chemotherapy administered with prophylactic anticoagulation. 16, 75 Furthermore, studies of genetic susceptibility loci for cisplatin-associated VTEs should be considered in efforts to personalize therapy. Finally, improved reporting of VTEs in clinical trials should be considered to better define the excess risk of VTEs associated with new and existing therapies. 
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